Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Current Role of Ivabradine in Stable Coronary Artery Disease Without Heart Failure.

Literature DB >> 26768739

Current Role of Ivabradine in Stable Coronary Artery Disease Without Heart Failure.

Mateo Porres-Aguilar¹, Oscar C Muñoz², Aamer Abbas².

Abstract

Increase in heart rate represents a significant contribution in the pathophysiology of coronary artery disease and heart failure, by promoting atherosclerotic process and endothelial dysfunction. Thus, it negatively influences cardiovascular risk in the general population. The aim of this review is to analyze the current, controversial, and future role of ivabradine as an anti-anginal agent in the setting of coronary artery disease without heart failure. Ivabradine represents a selective heart rate-lowering agent that increased diastolic perfusion time and improving energetics in the ischemic myocardium.

Entities: Chemical Disease

Keywords: Coronary artery disease; Heart failure; Heart rate; Ivabradine

Mesh：

Substances：

Year: 2016 PMID： 26768739 DOI： 10.1007/s11886-015-0689-2

Source DB: PubMed Journal: Curr Cardiol Rep ISSN： 1523-3782 Impact factor: 2.931

Keyword Cloud
References

18 in total

1. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.

Authors: Gilles Montalescot; Udo Sechtem; Stephan Achenbach; Felicita Andreotti; Chris Arden; Andrzej Budaj; Raffaele Bugiardini; Filippo Crea; Thomas Cuisset; Carlo Di Mario; J Rafael Ferreira; Bernard J Gersh; Anselm K Gitt; Jean-Sebastien Hulot; Nikolaus Marx; Lionel H Opie; Matthias Pfisterer; Eva Prescott; Frank Ruschitzka; Manel Sabaté; Roxy Senior; David Paul Taggart; Ernst E van der Wall; Christiaan J M Vrints; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Juhani Knuuti; Marco Valgimigli; Héctor Bueno; Marc J Claeys; Norbert Donner-Banzhoff; Cetin Erol; Herbert Frank; Christian Funck-Brentano; Oliver Gaemperli; José R Gonzalez-Juanatey; Michalis Hamilos; David Hasdai; Steen Husted; Stefan K James; Kari Kervinen; Philippe Kolh; Steen Dalby Kristensen; Patrizio Lancellotti; Aldo Pietro Maggioni; Massimo F Piepoli; Axel R Pries; Francesco Romeo; Lars Rydén; Maarten L Simoons; Per Anton Sirnes; Ph Gabriel Steg; Adam Timmis; William Wijns; Stephan Windecker; Aylin Yildirir; Jose Luis Zamorano
Journal: Eur Heart J Date: 2013-08-30 Impact factor: 29.983

Review 2. Rest heart rate and life expectancy.

Authors: H J Levine
Journal: J Am Coll Cardiol Date: 1997-10 Impact factor: 24.094

3. The role of heart rate may differ according to pathophysiological setting: from SHIFT to SIGNIFY.

Authors: Roberto Ferrari; Kim M Fox
Journal: Eur Heart J Date: 2015-04-28 Impact factor: 29.983

4. Changes in diastolic time with various pharmacologic agents: implication for myocardial perfusion.

Authors: H Boudoulas; S E Rittgers; R P Lewis; C V Leier; A M Weissler
Journal: Circulation Date: 1979-07 Impact factor: 29.690

5. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.

Authors: Jean-Claude Tardif; Ian Ford; Michal Tendera; Martial G Bourassa; Kim Fox
Journal: Eur Heart J Date: 2005-10-07 Impact factor: 29.983

6. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.

Authors: Karl Swedberg; Michel Komajda; Michael Böhm; Jeffrey Borer; Michele Robertson; Luigi Tavazzi; Ian Ford
Journal: J Am Coll Cardiol Date: 2012-05-29 Impact factor: 24.094

7. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.

Authors: Witold Ruzyllo; Michal Tendera; Ian Ford; Kim M Fox
Journal: Drugs Date: 2007 Impact factor: 9.546